Regeneron Pharmaceuticals (REGN) Osake Kurssi

Regeneron Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

The main competitors of Regeneron Pharmaceuticals Inc in the market include major pharmaceutical companies like Roche Holding AG, Amgen Inc, and Pfizer Inc. These companies are also involved in the development and commercialization of biopharmaceutical products, competing within the same therapeutic areas as Regeneron.

Regeneron Pharmaceuticals Inc, founded in 1988, is a renowned American biotechnology company specializing in the discovery, development, and commercialization of innovative medicines. Headquartered in Tarrytown, New York, Regeneron has a rich history of pioneering scientific breakthroughs. The company's success can be attributed to its robust research and development initiatives, focusing on various therapeutic areas such as oncology, ophthalmology, cardiovascular diseases, and rare genetic disorders. Regeneron's remarkable achievements include the development of EYLEA® (a leading treatment for retinal diseases) and the groundbreaking antibody cocktail, REGN-COV2, used for COVID-19 treatment. Renowned for its dedication to rigorous scientific research, Regeneron Pharmaceuticals Inc has established itself as a leader in the biopharmaceutical industry.

Regeneron Pharmaceuticals Inc. has achieved several significant milestones since its inception. Notably, the company received FDA approval for its groundbreaking drug, EYLEA®, in 2011, which revolutionized the treatment of age-related macular degeneration. Regeneron also gained recognition for the development of its therapy, Dupixent®, for atopic dermatitis, asthma, and other allergic conditions. In addition, the company has made significant advancements in the field of immuno-oncology with its innovative drug, Libtayo®, approved for the treatment of certain types of skin and lung cancers. Regeneron continues to drive progress in the biopharmaceutical industry by focusing on novel research and development initiatives.

Regeneron Pharmaceuticals Inc primarily operates in various countries and regions around the world. The company has a global presence with key markets in the United States, Europe, and other international locations. Through its strong partnerships and collaborations, Regeneron has expanded its reach and established a significant presence in the biopharmaceutical industry. With its dedication to scientific innovation and breakthrough treatments, Regeneron Pharmaceuticals Inc continues to make a meaningful impact on patients' lives worldwide.

Regeneron Pharmaceuticals Inc is a leading biotechnology company that values innovation, integrity, and collaboration. With a corporate philosophy centered around science-driven discoveries and patient-focused solutions, Regeneron aims to improve lives through its research and development of therapeutic products. They prioritize the use of cutting-edge technologies to address unmet medical needs and strive to deliver impactful medicines to patients worldwide. Regeneron's commitment to transparency, ethical practices, and scientific excellence has established its reputation as a trusted and reliable healthcare partner.

Analyytikot asettavat tällä hetkellä Regeneron Pharmaceuticals-osakkeelle keskimääräisen tavoitehinnan 820,65 USD (mediaani: 800,00 USD), mikä merkitsee +0,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 37 analyytikkoarvioon.

Regeneron Pharmaceuticals Analyytikkojen kursstavoitteet 2026

37 analyytikkoa arvioi tällä hetkellä Regeneron Pharmaceuticals-osaketta: 26 suosittaa ostoa, 11 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Regeneron Pharmaceuticals-yhtiöltä 17,65 Mrd. USD liikevaihtoa ja 58,23 USD osakekohtaista tulosta.

Regeneron Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Regeneron Pharmaceuticals-osake noteerataan hintaan 732,41 EUR (816,10 USD).

Regeneron Pharmaceuticals-osake (REGN) on listattuna 11 pörssissä, muun muassa: NASDAQ (REGN), London (0R2M.L), SIX (Zürich) (RGO.SW), XETRA (RGO.DE), Frankfurt (RGO.F), München (RGO.MU), Düsseldorf (RGO.DU), Hamburg (RGO.HM).

Regeneron Pharmaceuticals is a biotechnology company based in the United States that focuses on researching, developing, and marketing medications. It was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into various business divisions that address different medical conditions. This includes the field of ophthalmology, where Regeneron has developed the medication Eylea®, an effective treatment for age-related macular degeneration and other eye diseases. The sales in this area amounted to approximately $7.7 billion in 2020. Another important area is oncology, where Regeneron has developed the cancer medication Libtayo®, which is used to treat skin cancer and lung cancer. The sales in this area amounted to approximately $340 million in 2020. Regeneron is also involved in inflammation diseases, genetic diseases, and infectious diseases. The company has several promising medications in development in these areas, including a treatment for COVID-19. Regeneron collaborates closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with whom Regeneron has already brought several successful medications to the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, the R&D expenditure amounted to approximately $3.7 billion, which is about 40 percent of the total revenue. The company employs a large number of scientists and researchers who are constantly working on new medications. Regeneron also values the promotion of young talent. The company has established an extensive scholarship program specifically targeted at students and young scientists. This ensures that highly qualified professionals will be available in the future to further advance the company. In summary, Regeneron's business model specializes in research and development of new medications. The company works closely with various partners and has already brought several promising medications to the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers. Regeneron Pharmaceuticals is a US biotechnology company that specializes in the research, development, and marketing of medications. The company was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into several business areas that deal with different medical conditions. This includes the field of ophthalmology, in which Regeneron has developed the effective drug Eylea® for age-related macular degeneration and other eye diseases. Sales in this area were around $7.7 billion in 2020. Another important area is oncology, in which Regeneron has developed the cancer drug Libtayo®, which is used to treat skin cancer and lung cancer. Sales in this area were around $340 million in 2020. Other business areas of Regeneron include inflammatory diseases, genetic diseases, and infectious diseases. In these areas, the company has already developed several promising drugs, including a treatment for COVID-19. Regeneron works closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with which Regeneron has already successfully launched several drugs on the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, R&D spending was around $3.7 billion, approximately 40 percent of total revenue. The company employs a large number of scientists and researchers who are constantly working on new drugs. Regeneron also places great importance on promoting young talent. The company has launched an extensive scholarship program specifically targeting students and young scientists. This is to ensure that highly qualified professionals are available in the future to further advance the company. In conclusion, Regeneron's business model specializes in the research and development of new medications. The company works closely with various partners and has already launched several promising drugs on the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers.

odotettu liikevaihto Regeneron Pharmaceuticals on 17,65 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Regeneron Pharmaceuticals on 6,26 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Regeneron Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä 14,02. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Regeneron Pharmaceuticals-osakkeen arvostusta.

Regeneron Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,97. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Regeneron Pharmaceuticals-osakkeen arvostuskennuslukuna.

Regeneron Pharmaceuticals:n Eulpool-laatuscore on 6/10.

Regeneron Pharmaceuticals:n ISIN on US75886F1075. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Regeneron Pharmaceuticals:n WKN on 881535. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Regeneron Pharmaceuticals:n ticker on REGN. Tämä pörssinoteeraus käytetään Regeneron Pharmaceuticals-osakkeiden kauppaan pörssissä.